Opens in a new tab

Emboline v AorticLab (CFI, 16 April 2025)

Date16 April 2025
CourtCFI
DivisionMunich (DE) Local Division
Type of actionGeneric application
Registry referenceApp_8962/2025 · ORD_9097/2025
PartiesEmboline, Inc.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 16 April 2025 (UPC_CFI_628/2024, App_8962/2025), Judge-rapporteur Pichlmaier of the Munich Local Division ordered AorticLab, defendant to Emboline’s infringement action on EP 2 129 425 and counterclaimant for revocation, to provide security of EUR 200,000 for Emboline’s costs. The deadline is two weeks after service of any Court of Appeal decision upholding the order, or 31 May 2025 if no appeal is lodged. Leave to appeal was granted. The order accepts that an infringement claimant may obtain security in its capacity as defendant to the counterclaim.

Question

May the infringement claimant, as defendant to the counterclaim for revocation, obtain security for costs under Art. 69(4) UPCA, and does the defendant’s own statement that it fears insolvency justify it?

Decision

The judge left open whether the Düsseldorf practice, under which each party may request security, is consistent with Art. 69(4), which refers to a request « of the defendant ». In any event, Emboline is also a defendant: under the UPCA a claimant is also whoever brings a revocation action or a counterclaim for revocation (Art. 32(1)(d) and (e)), and Art. 33(8) calls the counterclaimant the applicant. Under the Court of Appeal’s test, AorticLab’s own statement that an injunction would drive it into insolvency gives rise to a legitimate and real concern that a costs order may not be recoverable, since the costs order would follow the injunction. The amount reflects the recoverable costs for a counterclaim value of up to EUR 2 million.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 32(1)(a), (d) and (e), 33(8) and 69(4)
Rules of Procedure
Rules 158, 220.2 and 355
Case law cited
Court of Appeal, UPC_CoA_217/2024

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Written procedure (UPC), Court fees and costs (UPC).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Generic application
Outcome (Dhenne Avocats summary)
AorticLab doit constituer une garantie de 200 000 EUR pour les frais d'Emboline, défenderesse à la demande reconventionnelle. L'autorisation d'appel est accordée.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 129 425Mentioned in the analysis (role not qualified)
Also mentioned in 5 other decision(s): AorticLab v Emboline (CoA, 17 August 2026) · Emboline v AorticLab (CoA, 16 July 2026) · Emboline v AorticLab (CFI, 13 January 2026) · AorticLab v Emboline (CoA, 20 June 2025) · Emboline v AorticLab (CoA, 28 September 2026)
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.